Experimental chest injection aims to stop cancer fluid buildup

NCT ID NCT07332858

Recruiting now Disease control Sponsor: Gang Hou Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a drug called TolueneSulfonamide, injected directly into the chest cavity, to see if it can safely reduce fluid buildup in people with lung cancer. About 105 participants will receive the drug three times a week for one week. The goal is to control the fluid and ease breathing, but the main focus is on safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TolueneSulfonamide (a chemical compound injected into the chest cavity)
What this could lead to: If it works, this could offer a new way to control fluid buildup in the chest caused by lung cancer, reducing breathing difficulty.
What could go wrong: This is a very early (Phase 1/2) study with only 105 people. The drug may not work or could cause side effects like chest pain or infection. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL EFFUSIONS (MPE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myeloproliferative disorder, chronic, with eosinophilia non-small cell lung carcinoma Pleural Effusion, Malignant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT PLEURAL EFFUSIONS (MPE) NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

China-Japan Friendship Hospital
RECRUITING

Beijing, Beijing Municipality, 100029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.